Related Experiment Video
Updated: Sep 28, 2026

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis
Published on: July 28, 2023
Evaluation of a commercially available serologic assay for antibodies against tuberculosis-associated glycolipid
Yoshitsugu Iinuma1, Kazuyoshi Senda, Shunji Takakura
1Department of Clinical Laboratory, Nagoya University Hospital, Nagoya-city, Japan. yiinuma@med.nagoya-u.ac.jp
Abstract:
A commercially available enzyme immunoassay developed to detect antibodies to a tuberculosis-associated glycolipid antigen was evaluated for serologic diagnosis of tuberculosis. This was a multicenter study comparing the assay with other methods in 78 patients with active pulmonary tuberculosis and in 54 controls with non-tuberculous lung diseases. Sensitivities were highest for sputum culture (91.0%), followed by immunoassay (79.5%), nucleic acid amplification (77.3%), and finally acid-fast staining of sputum smear (60.3%). Immunoassay and amplification, both rapid methods, had similarly high sensitivity in smear-positive subjects (89.4 and 88.9%, respectively); in smear-negative subjects these two techniques showed low sensitivity (64.5 and 60.0%, respectively). Concordance between the two methods was relatively low (72.0%). With regard to specificity, seven out of ten patients with old tuberculosis had positive result by immunoassay (30% specificity). In the control group, 10 out of 54 patients had positive immunoassay result (72.2% specificity), with notably limited specificity in the elderly. The tuberculous glycolipid assay is a rapid method sufficiently sensitive for detection of tuberculosis infection, even in smear-negative patients.
